Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 03, 2022 3:48pm
150 Views
Post# 34279968

RE:RE:New year

RE:RE:New year Yeah, so much for the buying spring-back!  Tax sellers are either staying away for good, just lowering exposure or exiting, or will sit back and wait for any news. We have obviously taken the "optimistic" view around all of this, but one could still view the last 6 months very pessimistically if you wanted to, and that's in play until any new PR. 

Clearly there haven't been loads of treatment-related deaths or they would have to inform the market I believe. But given it's first in human and they've chosen to basically create a fairly big information vacuum other than the small tidbits mentioned in those conferences, the whole wide gamut of possibilities is still in play to some degree or another. I would guess there really weren't any other data points they could give or talk about --it just was way behind their schedule. It's a shame their already tiny followership continues to shrink more.  Those shareholders likely won't come back, so it's reset back at this $3 level again. Groundhog Day must be their favorite movie....




Bucknelly21 wrote: Although small the selling is continued 


<< Previous
Bullboard Posts
Next >>